April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Effect of Correction Formulas for Corneal Properties on the Magnitude of Intraocular Pressure Reduction from Topical Prostaglandin Therapy
Author Affiliations & Notes
  • Daniel R. Agarwal
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • Joshua R. Ehrlich
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • Mitsugu Shimmyo
    Ophthalmology, New York Medical College, New York, New York
  • Nathan M. Radcliffe
    Ophthalmology, Weill Cornell Medical College, New York, New York
  • Footnotes
    Commercial Relationships  Daniel R. Agarwal, Instrument support from Reichert, Inc. (F); Joshua R. Ehrlich, Instrument support from Reichert, Inc. (F); Mitsugu Shimmyo, Instrument support from Reichert, Inc. (F); Nathan M. Radcliffe, Consultant for Allergan, Inc. and Alcon, Inc. (C), Instrument support from Reichert, Inc. (F)
  • Footnotes
    Support  American Glaucoma Society; Medical Student Training in Aging Research Program; Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 664. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniel R. Agarwal, Joshua R. Ehrlich, Mitsugu Shimmyo, Nathan M. Radcliffe; Effect of Correction Formulas for Corneal Properties on the Magnitude of Intraocular Pressure Reduction from Topical Prostaglandin Therapy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):664.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Investigators have proposed distinct formulas to correct IOP for corneal bio-structural and mechanical properties including central corneal thickness (CCT) and corneal hysteresis (CH). We sought to determine whether the use of several published corneal correction formulas would result in different measurements of the magnitude of IOP reduction from ocular hypotensive therapy.

Methods: : 61 consecutive patients with open-angle glaucoma who were treatment naïve and initiated on a prostaglandin analog (PGA) underwent examination with the Ocular Response Analyzer (ORA; Reichert, Corp., Buffalo, NY) at baseline (untreated) and at follow-up (treated). IOP correction formulas included ORA-generated corneal compensated IOP (IOPcc) and three published formulas(1-3) to adjust for the impact of CCT, assuming either a linear(1,2) or logarithmic(2,3) relationship between corneal properties and IOP.

Results: : Goldmann-correlated IOP (IOPg) unadjusted for corneal properties was reduced by 4.0 mm Hg (22.3%) from 17.9 mm Hg at baseline to 13.9 mm Hg after treatment (p<0.001). Baseline CCT was 542.4 µm and baseline CH was 9.5 mm Hg. IOPg corrected for CCT using the three cited formulas declined by 4.01, 4.01, and 4.05 mm Hg respectively while IOPcc declined by 4.28 mm Hg. Compared to unadjusted IOPg, there was no significant difference in the amount of IOPg reduction with adjustment for corneal properties (p≥0.15, pairwise comparisons), nor were there significant differences in the magnitude of IOPg reduction between correction formulas (p≥0.15, pairwise comparisons).

Conclusions: : Adjustment of IOP for corneal properties results in significantly different IOP values, however correction formulas did not significantly impact the magnitude of IOP reduction following initiation of PGA therapy. This study suggests that cross-sectional correction of IOP could impact the determination of target IOPs but that IOP correction may be less useful in longitudinally gauging treatment response.1. Kohlhaas M, et al. Arch Ophthalmol. 2006;124(4):471-476.2. Ko Y, et al. Eye. 2004;19(3):327-332.3. Shimmyo M, et al. Am J Ophthalmol. 2003;136(4):603-613.

Keywords: intraocular pressure • cornea: clinical science • detection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×